Nektar Therapeutics (NASDAQ: NKTR)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Nektar Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Nektar Therapeutics Company Info
A biopharmaceutical company which develops breakthrough products that make a difference in patients lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.
News & Analysis
The company is throwing in the towel on its lead pipeline program.
A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.
The company's Q3 revenue was lower than expected.
These stocks have one obvious thing in common.
New combination trials bring hope for patients and investors.
The biotech topped Wall Street estimates, but the real focus was on its pipeline.
In a 27-0 shutout, the advisory committee voted against approval of the company's pain drug, oxycodegol.
The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
NKTR earnings call for the period ending September 30, 2021.
NKTR earnings call for the period ending June 30, 2021.
NKTR earnings call for the period ending March 31, 2021.
NKTR earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.